Biotech companies are difficult to evaluate or analyze due to the speculative nature of their technologies and due to the breadth of knowledge, experience, and education required to understand these. Although this is true for all industries, it is particularly true for biotech.
Specifically, genomics is one niche within the biotech group that could offer unimaginable returns. Still, the technology is so new and so advanced many investors shy away from companies that are making astounding advancements. One solution is to delegate individual stock picking to the professionals.
In this article, we’ll compare two ETFs to consider for our readers looking to gain access to companies at the forefront of genomics innovation but don’t have time to research the field and the companies within it.
ARK Genomic Revolution ETF (ARKG)
ARKG reaches across multiple sectors, and geographies for companies that the advisor believes will benefit from innovations in the genomics-related industry. Such companies are those that may develop, produce or enable targeted therapeutics, bioinformatics, stem cells, or molecular diagnostics. The reality is almost all of its holdings are in US healthcare-related companies, with biotech naturally leading the way. This is a niche fund that employs an actively-managed strategy. The advisory firm, led by Catherine Wood, has an impressive track record doing what most stock pickers fail to do: beating the market.
- Weighted Average Market Cap $51.89B
- Price / Earnings Ratio -76.34
- Price / Book Ratio 5.49
- YTD Daily Total Return -7.12%
- Yield 0.89%
- Expense Ratio 0.75
- Net Assets 9.44B
- Number of Holdings 57
- Top Holdings: Teladoc TDOC, Exact Sciences EXAS, Pacific Biosciences PACB
iShares Genomics Immunology and Healthcare ETF (IDNA)
IDNA holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. In addition to these industry screens, companies must also meet certain size and liquidity measures for index eligibility. The underlying index then assigns a “Relationship Keyword Score” to each eligible company using the FactSet Supply Chain Relationships database to search for keywords related to ‘Genomics and Immuno Biopharmaceutical’ products and technologies. The top 50 names with the highest scores are included in the index. Holdings are weighted by market cap and are constrained such that no individual security exceeds the 4% weight of the portfolio. The index rebalances semi-annually.
- Weighted Average Market Cap $21.18B
- Price / Earnings Ratio -40.20
- Price / Book Ratio 5.01
- YTD Daily Total Return -1.39%
- Yield 0.26%
- Expense Ratio 0.47%
- Net Assets 287.46M
- Number of Holdings 51
- Top Holdings: BeiGene Ltd BGNE, Fate Therapeutics FATE, Exelixis Inc. EXEL
Beyond the active/passive difference, IDNA’s holdings are dominated by major pharmaceutical firms like Moderna (MRNA), Regeneron (REGN), and Gilead Sciences (GILD). In contrast, ARKG’s portfolio is tilted toward significantly smaller firms.
There isn’t a lot of performance history to compare, but it’s worth noting that IDNA beat ARKG in the first ten weeks of 2020 when global markets were rocked by the coronavirus outbreak and investors were eagerly hunting for potential profit in companies researching treatment and vaccines.
But that’s just a fleeting snapshot during a particularly turbulent time. Any actively-managed product is ultimately a bet on the portfolio managers who pick the stocks. ARK’s products are geared toward investors with the fortitude and faith to ride out short-term blips in favor of the prospect long-term alpha.
Should you invest in ARKG right now?
Before you consider buying ARKG, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not ARKG.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
Click here to watch his presentation, and decide for yourself...
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
Click here to find out the name and ticker of Keith's #1 pick...
